id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0060,FDA,FDA-2007-D-0369,"Cited References - [Warner Chilcott (US), LLC - Comment]  re FDA-2007-D-0369-0044",Supporting & Related Material,Electronic Regulation from Form,2011-07-14T04:00:00Z,2011,7,,,2011-07-14T16:38:18Z,,0,0,0900006480a8d3d0
FDA-2007-D-0369-0059,FDA,FDA-2007-D-0369,"Cited References - [Warner Chilcott (US), LLC - Comment]  re FDA-2007-D-0369-0043",Supporting & Related Material,Electronic Regulation from Form,2011-07-14T04:00:00Z,2011,7,,,2011-07-14T16:35:31Z,,0,0,0900006480a8d3cf
FDA-2007-D-0369-0052,FDA,FDA-2007-D-0369,"Attachment 1 - ""Draft Guidance on Rivastigmine"" - [Novartis Pharmaceuticals Corporation - Comment]  re FDA-2007-D-0369-0051",Supporting & Related Material,C-Comment (Supporting and Related Material),2011-01-31T05:00:00Z,2011,1,,,2011-01-31T22:17:38Z,,0,0,0900006480b82b4e
FDA-2007-D-0369-0053,FDA,FDA-2007-D-0369,"Attachment 3 - ""Exelon Patch (Rivastigmine Transdermal System)"" - [Novartis Pharmaceuticals Corporation - Comment]  re FDA-2007-D-0369-0051",Supporting & Related Material,C-Comment (Supporting and Related Material),2011-01-31T05:00:00Z,2011,1,,,2011-01-31T22:17:40Z,,0,0,0900006480b82b50